Global Inhaled Corticosteroid Device Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• April 2021: Breath-actuated dry powder inhalers (BADPIs) have been one of the several latest innovations in the market. These inhalers only release medication when the patient inhales, eliminating the need for breath coordination and potentially improving drug delivery to the lungs.

• In July 2023, Hormosan Pharma GmbH, a subsidiary of Lupin, launched Luforbec, a pressurized metered-dose inhaler in Germany. Luforbec is indicated for adult asthma and COPD treatment, combining an inhaled corticosteroid and a long-acting beta2-agonist.

The Types segment of the market includes several inhaler devices designed to deliver corticosteroids effectively to the lungs. These include Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Nebulizers. MDIs are widely used due to their portability and ease of use, delivering a pre-measured dose of medication with each inhalation. DPIs, on the other hand, deliver powdered medication without the need for a propellant, making them more environmentally friendly. Nebulizers are used for patients with more severe respiratory conditions and are preferred in clinical settings due to their ability to deliver larger doses over a longer period. The growing preference for specific inhalation devices based on the severity of conditions and ease of use drives market demand across these types.

In terms of Indication, inhaled corticosteroids are primarily used for managing asthma and chronic obstructive pulmonary disease (COPD). ICS are considered the first-line treatment for both conditions due to their anti-inflammatory properties, which help reduce airway inflammation and prevent exacerbations. As the prevalence of asthma and COPD continues to rise globally, especially in aging populations and those exposed to environmental pollutants, the demand for inhaled corticosteroid devices remains strong. Additionally, the growing awareness of the benefits of ICS in preventing flare-ups and improving overall lung function contributes to market expansion.

The Applications of inhaled corticosteroid devices are closely linked to their role in treating chronic respiratory conditions. ICS devices are used in preventive care to reduce inflammation and control symptoms in both asthma and COPD patients. They are also essential in maintenance therapy, aiming to prevent long-term complications associated with these diseases. ICS devices are integrated into daily treatment regimens for both adult and pediatric patients. With ongoing research and development, ICS devices are also being explored for other potential applications in treating conditions such as allergic rhinitis and nasal polyps, which further broadens their market scope.

In terms of End-Users, the primary users of inhaled corticosteroid devices are hospitals and clinics, where they are administered under the supervision of healthcare professionals. These devices are commonly used in emergency care settings for acute asthma or COPD attacks. In addition, homecare settings are increasingly becoming a significant end-user segment as patients with chronic respiratory conditions prefer self-administration. With the rise of telemedicine and patient education programs, home use of ICS devices is expected to continue growing, allowing patients to manage their conditions independently. The pharmacy sector also plays a crucial role in distributing ICS devices to consumers, further supporting the market’s expansion.

Together, these segments highlight the comprehensive nature of the inhaled corticosteroid device market, where device types, indications, and applications are closely linked to the needs of different patient groups and healthcare settings. As demand for effective respiratory treatments increases globally, the market for ICS devices is expected to grow steadily.

Global Inhaled Corticosteroid Device Segment Analysis

In this report, the Global Inhaled Corticosteroid Device Market has been segmented by Types, Indication, Applications, End-Users, and Geography.

Global Inhaled Corticosteroid Device Market, Segmentation by Types

The Global Inhaled Corticosteroid Device Market has been segmented by Types into Beclomethasone Dipropionate, Budesonide, Fluticasone Inhaler Powder, and Mometasone.

Beclomethasone dipropionate is a synthetic corticosteroid commonly delivered via inhalation for its anti-inflammatory properties, reducing airway inflammation and improving respiratory symptoms. Available in various inhalation device formulations such as pressurized metered-dose inhalers (pMDIs) and dry powder inhalers (DPIs), beclomethasone dipropionate is widely used for the maintenance treatment of asthma and COPD, offering efficacy and safety in controlling airway inflammation and preventing exacerbations.

Budesonide is another widely prescribed corticosteroid medication delivered via inhalation for the treatment of respiratory inflammatory conditions. Known for its potent anti-inflammatory effects, budesonide is available in various inhalation device formulations such as pMDIs, DPIs, and nebulizers, offering flexibility and convenience in administration. Budesonide inhalation therapy is indicated for asthma, COPD, and other inflammatory airway conditions, providing effective symptom control and improving lung function in patients with chronic respiratory diseases.

Fluticasone inhaler powder represents another key segment within the inhaled corticosteroid device market, offering a potent corticosteroid medication delivered via dry powder inhalers (DPIs) for the management of asthma and COPD. Fluticasone inhaler powder is known for its long-acting anti-inflammatory effects, reducing airway inflammation and preventing exacerbations in patients with respiratory diseases. With advancements in DPI technology and formulation design, fluticasone inhaler powder offers improved drug delivery efficiency and patient adherence, contributing to better treatment outcomes and respiratory symptom control.

Mometasone is a synthetic corticosteroid medication delivered via inhalation for the treatment of inflammatory airway conditions such as asthma and allergic rhinitis. Mometasone inhalation therapy is available in various inhalation device formulations, including pMDIs and DPIs, offering efficacy and safety in controlling airway inflammation and improving respiratory symptoms. With its potent anti-inflammatory effects and favorable safety profile, mometasone inhalation therapy is widely used as a maintenance treatment for asthma and COPD, providing long-term symptom control and improving quality of life for patients with chronic respiratory diseases.

Global Inhaled Corticosteroid Device Market, Segmentation by Indication

The Global Inhaled Corticosteroid Device Market has been segmented by Indication into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others.

In the Asthma segment, inhaled corticosteroid devices are primarily used to manage inflammation in the airways, which is a core characteristic of asthma. ICS are often the first-line treatment for asthma as they help reduce symptoms, prevent exacerbations, and improve lung function. The growing prevalence of asthma worldwide, particularly in children and urban populations exposed to air pollution, is driving the demand for inhaled corticosteroid devices. Asthma patients typically rely on ICS for long-term control, using these devices on a daily basis to maintain symptom-free periods and prevent severe asthma attacks.

In the Chronic Obstructive Pulmonary Disease (COPD) segment, ICS devices are used to manage symptoms and reduce the frequency of exacerbations. COPD, which includes conditions like emphysema and chronic bronchitis, is characterized by persistent airflow limitation and chronic inflammation in the airways. ICS are a cornerstone in the treatment of COPD, helping to decrease inflammation and improve the quality of life for patients. With the increasing prevalence of COPD, particularly among the aging population and those with a history of smoking, there is growing demand for ICS devices. These devices are used not only for maintenance therapy but also to prevent flare-ups, which are a major cause of hospitalizations for COPD patients.

The Others segment includes indications beyond asthma and COPD, such as allergic rhinitis, nasal polyps, and other inflammatory respiratory conditions. Although ICS devices are not the primary treatment for these conditions, they can be used to reduce inflammation and improve symptoms in cases where corticosteroid therapy is needed. As research into the broader applications of ICS continues, the market for inhaled corticosteroid devices may expand to treat additional respiratory and nasal disorders. The increasing focus on managing conditions like allergic rhinitis with ICS devices will drive growth in this segment, particularly as awareness of the efficacy of ICS for such indications increases.

Together, these segments illustrate the role of inhaled corticosteroid devices in managing a range of respiratory conditions. The growing burden of asthma and COPD, coupled with the potential for broader applications, is expected to fuel sustained demand in the ICS device market.

Global Inhaled Corticosteroid Device Market, Segmentation by Applications

The Global Inhaled Corticosteroid Device Market has been segmented by Applications into Asthma and COPD (Chronic Obstructive Pulmonary Disease).

Asthma represents a significant application segment within the inhaled corticosteroid device market, encompassing a diverse range of patients with varying degrees of disease severity and control. Inhaled corticosteroids are recommended as first-line maintenance therapy for patients with persistent asthma, providing long-term control of symptoms and reducing the risk of asthma exacerbations. These medications are delivered via inhalation devices such as pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs), offering convenience, efficacy, and safety in managing asthma symptoms. With advancements in inhaler technology and formulation design, inhaled corticosteroids continue to play a pivotal role in asthma management, offering personalized treatment options tailored to individual patient needs and preferences.

Chronic obstructive pulmonary disease (COPD) represents another key application segment within the inhaled corticosteroid device market, comprising a heterogeneous group of patients with chronic bronchitis, emphysema, or a combination of both conditions. Inhaled corticosteroids are recommended as part of combination therapy for patients with moderate to severe COPD and a history of exacerbations, providing additional anti-inflammatory benefits to bronchodilator therapy. These medications are delivered via inhalation devices such as pMDIs, DPIs, and nebulizers, offering targeted delivery to the lungs and reducing systemic side effects associated with oral corticosteroid therapy. With a growing emphasis on personalized medicine and tailored treatment approaches, inhaled corticosteroids play a vital role in COPD management, offering symptom relief, improved lung function, and reduced exacerbation risk for patients with this chronic respiratory condition.

Global Inhaled Corticosteroid Device Market, Segmentation by End-Users

The Global Inhaled Corticosteroid Device Market has been segmented by End-Users into Hospitals, Clinics, and Respiratory Care Center.

Hospitals represent a significant end-user segment within the inhaled corticosteroid device market, serving as primary healthcare facilities equipped with advanced medical infrastructure and specialized respiratory care units. Hospitals provide comprehensive diagnostic, treatment, and rehabilitation services for patients with respiratory diseases, including asthma and COPD. Inhaled corticosteroid medications are frequently prescribed and administered to patients in hospital settings, often in conjunction with other respiratory therapies such as bronchodilators, oxygen therapy, and pulmonary rehabilitation. Hospitals also play a crucial role in managing acute exacerbations of asthma and COPD, providing emergency care and intensive treatment to stabilize patients and prevent further respiratory complications. With their multidisciplinary approach to respiratory care and access to advanced medical technology, hospitals are key stakeholders in the inhaled corticosteroid device market, contributing to improved patient outcomes and disease management.

Clinics represent another important end-user segment within the inhaled corticosteroid device market, encompassing various healthcare facilities such as primary care clinics, specialty respiratory clinics, and outpatient clinics. Clinics provide essential medical services, preventive care, and treatment options for patients with respiratory conditions, offering consultation, diagnosis, and medication management for asthma, COPD, and other lung diseases. Inhaled corticosteroid medications are commonly prescribed and dispensed to patients in clinic settings, often as part of long-term maintenance therapy for managing chronic respiratory symptoms and preventing exacerbations. Clinics also play a critical role in patient education, counseling, and adherence monitoring, helping individuals with respiratory diseases understand their condition, manage their symptoms, and improve their quality of life. With their focus on patient-centered care and accessibility, clinics serve as important distribution channels for inhaled corticosteroid devices, ensuring widespread availability and utilization of these essential respiratory therapies.

Respiratory care centers represent a specialized segment within the inhaled corticosteroid device market, dedicated to providing comprehensive respiratory care services to patients with complex respiratory conditions and specialized medical needs. These centers offer advanced diagnostic testing, treatment modalities, and therapeutic interventions for a wide range of respiratory diseases, including severe asthma, COPD, cystic fibrosis, and pulmonary fibrosis. Inhaled corticosteroid medications are integral components of the treatment regimens prescribed in respiratory care centers, often used in combination with other respiratory therapies such as biologic agents, airway clearance techniques, and supplemental oxygen therapy. Respiratory care centers employ specialized healthcare professionals, including pulmonologists, respiratory therapists, and nurse practitioners, who collaborate to deliver individualized care plans tailored to each patient's unique respiratory needs. With their expertise in managing complex respiratory conditions and access to state-of-the-art medical technology, respiratory care centers play a critical role in optimizing patient outcomes and improving respiratory health outcomes. As key stakeholders in the inhaled corticosteroid device market, these centers contribute to advancing respiratory medicine and enhancing the quality of care for patients with respiratory diseases.

Global Inhaled Corticosteroid Device Market, Segmentation by Geography

In this report, the Global Inhaled Corticosteroid Device Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Inhaled Corticosteroid Device Market Share (%), by Geographical Region, 2024

North America emerges as a prominent market for inhaled corticosteroid devices, fueled by advanced healthcare infrastructure, high prevalence of respiratory diseases, and strong research and development activities in pharmaceuticals. The United States and Canada lead in market share, supported by robust regulatory frameworks, extensive healthcare coverage, and widespread adoption of inhaled corticosteroid therapies. With a growing emphasis on personalized medicine, patient-centered care, and innovative drug delivery technologies, North America continues to drive market growth in the inhaled corticosteroid device segment, attracting investments from key market players and fostering collaborations between academia, industry, and healthcare providers.

Europe represents another significant market for inhaled corticosteroid devices, characterized by well-established healthcare systems, high healthcare expenditure, and increasing prevalence of respiratory diseases. Major European countries such as the United Kingdom, Germany, France, Italy, and Spain contribute to market growth, driven by initiatives to improve respiratory health, enhance patient access to inhalable therapies, and promote research and innovation in respiratory medicine. With advancements in inhaler technology and formulation science, Europe offers a fertile ground for market expansion and innovation in the inhaled corticosteroid device segment, addressing the evolving needs of patients and healthcare providers across the region.

The Asia Pacific region presents lucrative growth opportunities for the inhaled corticosteroid device market, driven by factors such as increasing healthcare expenditure, rising prevalence of respiratory diseases, and expanding access to healthcare services. Countries such as China, India, Japan, and Australia are witnessing growing demand for inhaled corticosteroid therapies, fueled by urbanization, air pollution, and lifestyle changes contributing to respiratory health issues. Additionally, advancements in healthcare infrastructure, government initiatives to improve respiratory health, and growing awareness about inhalable drug therapies contribute to market expansion in the Asia Pacific region. With a large and diverse population base, Asia Pacific offers significant growth potential for market players, supported by efforts to address unmet medical needs and improve patient outcomes through innovative inhalable therapies.

Latin America and the Middle East and Africa also present growth opportunities for the inhaled corticosteroid device market, albeit with unique challenges and market dynamics. In Latin America, countries such as Brazil, Mexico, and Argentina are witnessing increasing demand for inhaled corticosteroid therapies, driven by rising healthcare expenditures, growing prevalence of respiratory diseases, and expanding access to healthcare services. Despite economic challenges and healthcare disparities, Latin America offers growth potential for market players, supported by efforts to improve healthcare infrastructure, enhance regulatory frameworks, and address unmet medical needs in respiratory care. Similarly, in the Middle East and Africa, countries such as the United Arab Emirates, South Africa, and Saudi Arabia are investing in healthcare infrastructure and expanding access to inhaled corticosteroid therapies, driven by factors such as increasing healthcare expenditure, rising awareness about respiratory health, and growing prevalence of chronic respiratory diseases. Overall, the geographic segmentation of the inhaled corticosteroid device market underscores regional disparities in healthcare access and highlights opportunities for market expansion and investment across different regions during the forecast period.

This report provides an in depth analysis of various factors that impact the dynamics of Global Inhaled Corticosteroid Device Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Increasing Demand for Asthma and COPD Management
• Technological Advancements in Inhalation Devices
• Growing Awareness About Inhaled Corticosteroid Therapy

• Emphasis on Preventive Healthcare Strategies - The emphasis on preventive healthcare strategies serves as a significant driver for the global inhaled corticosteroid device market. With the increasing recognition of the importance of early intervention and disease prevention, healthcare systems and providers are prioritizing preventive measures for respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Inhaled corticosteroids (ICS) play a crucial role in preventive therapy by reducing airway inflammation, minimizing exacerbations, and improving long-term disease control in patients with these chronic respiratory conditions. Consequently, there is growing demand for inhaled corticosteroid devices as part of comprehensive preventive healthcare strategies aimed at reducing disease burden and improving patient outcomes.

  The shift towards preventive healthcare strategies aligns with the broader trend towards patient-centered care and population health management. By focusing on preventive interventions, healthcare providers aim to identify and address risk factors for respiratory diseases early in the disease course, before symptoms become severe or irreversible. Inhaled corticosteroid devices enable targeted delivery of anti-inflammatory medications directly to the airways, thereby minimizing systemic side effects and maximizing therapeutic efficacy. This proactive approach to respiratory care not only improves individual patient outcomes but also reduces healthcare costs associated with emergency room visits, hospitalizations, and disease complications.

  The emphasis on preventive healthcare strategies creates opportunities for collaboration and partnership among healthcare stakeholders, including pharmaceutical companies, device manufacturers, healthcare providers, and patient advocacy groups. By working together, these stakeholders can develop and implement initiatives to raise awareness about the importance of preventive therapy, optimize treatment adherence, and improve patient education and self-management skills. Additionally, innovative approaches such as digital health technologies, telemedicine platforms, and remote patient monitoring enable proactive monitoring of respiratory symptoms, medication adherence, and disease progression, facilitating early intervention and personalized preventive care.

Restraints

• Safety Concerns Related to Corticosteroid Use
• Competition from Alternative Treatment Options
• Limited Reimbursement Coverage
• High Development Costs and Manufacturing Complexity -

  ### High Development Costs and Manufacturing Complexity

  High development costs and manufacturing complexity present significant challenges in the global inhaled corticosteroid device market. The research and development (R&D) process for inhaled corticosteroid devices involves extensive preclinical studies, clinical trials, and regulatory submissions to demonstrate safety, efficacy, and compliance with regulatory requirements. Additionally, the development of inhalation devices requires specialized expertise in aerosol science, engineering, and device design to optimize drug delivery efficiency, patient usability, and reliability. The complexity of device development adds to the overall development costs and time to market, posing financial and operational challenges for companies operating in this market.

  Moreover, manufacturing inhaled corticosteroid devices involves stringent quality control processes and adherence to Good Manufacturing Practice (GMP) regulations to ensure product quality, consistency, and sterility. The production of inhalation devices requires precision machining, assembly, and testing of components to meet regulatory standards and performance specifications. Additionally, the integration of drug formulations with inhalation devices adds complexity to the manufacturing process, requiring specialized equipment and facilities for drug formulation, filling, and packaging. The high manufacturing complexity increases production costs and operational risks, particularly for small and medium-sized manufacturers with limited resources and infrastructure.

  Furthermore, the high development costs and manufacturing complexity may deter innovation and market entry, particularly for smaller companies and startups in the inhaled corticosteroid device market. The significant upfront investment required for R&D, clinical trials, and manufacturing scale-up may pose financial barriers to entry for companies seeking to develop novel inhalation devices or drug-device combinations. Additionally, regulatory uncertainties and market access challenges further compound the risks associated with product development and commercialization. As a result, companies may be reluctant to invest in innovative technologies or pursue niche therapeutic indications, limiting market competition and innovation in the inhaled corticosteroid device market.

  In summary, addressing the challenges of high development costs and manufacturing complexity requires strategic investments in R&D infrastructure, manufacturing capabilities, and regulatory expertise. Collaboration and partnership opportunities with contract development and manufacturing organizations (CDMOs) can provide access to specialized resources and accelerate product development timelines. Additionally, leveraging advanced technologies such as additive manufacturing, automation, and digitalization can streamline manufacturing processes and improve cost efficiency in the production of inhaled corticosteroid devices.

Opportunities

• Development of Novel Corticosteroid Formulations
• Targeted Drug Delivery Systems for Respiratory Conditions
• Strategic Partnerships and Collaborations

• Focus on Personalized Medicine and Precision Inhalation Therapy - The increasing focus on personalized medicine and precision inhalation therapy is reshaping the landscape of the global inhaled corticosteroid device market. Personalized medicine seeks to tailor medical treatments to individual patient characteristics, including genetic makeup, biomarker profiles, and disease phenotypes. In the context of inhalation therapy, personalized medicine approaches involve the customization of treatment regimens based on patient-specific factors such as lung function, disease severity, and treatment response. By leveraging advanced diagnostic techniques, biomarker assays, and genomic profiling, healthcare providers can identify patients who are most likely to benefit from inhaled corticosteroid therapy and optimize treatment outcomes.

  The integration of personalized medicine and precision inhalation therapy is driving innovation and market differentiation in the inhaled corticosteroid device market. Pharmaceutical companies are investing in research and development efforts to identify novel drug targets, biomarkers, and therapeutic pathways associated with respiratory diseases. By adopting a pharmacogenomic approach, companies can stratify patient populations based on genetic variations that influence drug metabolism, receptor sensitivity, and disease susceptibility, enabling more precise selection of inhaled corticosteroid therapies. Additionally, real-time monitoring technologies, such as digital inhalers and remote patient monitoring systems, provide valuable insights into patient adherence, symptom control, and treatment response, facilitating personalized treatment adjustments and optimization of inhalation therapy regimens.

  The focus on personalized medicine and precision inhalation therapy is revolutionizing the treatment of respiratory diseases and driving innovation in the inhaled corticosteroid device market. By embracing patient-centric approaches, leveraging advanced technologies, and integrating multidisciplinary expertise, stakeholders can optimize therapeutic outcomes, improve patient satisfaction, and advance the field of respiratory medicine towards more individualized and effective care.

Key players in Global Inhaled Corticosteroid Device Market include :

• Plumage Therapeutics LLP
• Pearl Therapeutic Inc
• Teijin LTD
• Glaxos Advair
• Amgen Inc
• Kos Pharmaceutical
• Teva Pharmaceutical

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis